

1 **Making PROMs Practical for Clinical Use in Knee and Hip Osteoarthritis: Evaluating**
2 **Barriers to Use and Proposing BORIS - A Possible Solution**

3 Andrew P Savvas^a and Matthew G Liptak BMBS^{b, c}

4 ^a Adelaide Medical School, Adelaide, SA, Australia

5 ^b Orthopaedics SA, Adelaide, SA, Australia

6 ^c Flinders Medical Centre, Adelaide, SA, Australia

7 Corresponding Author: Andrew Savvas

8 Email: andrew.savvas@student.adelaide.edu.au

9 **Abstract**

10 Routine clinical use of patient reported outcome measures (PROMs) in knee and hip
11 osteoarthritis remains highly limited despite the benefits of use. This study builds upon
12 existing research exploring barriers to use through surveys completed by orthopaedic
13 surgeons, general practitioner and members of the general public. Informed by these surveys
14 and the literature, three novel and actionable strategies are proposed to guide development of
15 more clinically practical PROMs, these are (1) reducing length (2) incorporating symptom
16 severity stratification (3) embedding treatment and referral recommendation directly into the
17 PROM framework. These strategies aim to align with existing clinical workflows, rather than
18 opposing existing practices to retrofit current PROMs into the clinical environment. An
19 exemplar PROM, named the Basic Rapid Orthopaedic Indicator Score, is provided to
20 showcase how these strategies might be implemented.

21

22 **Keywords:** Osteoarthritis, Knee, Hip, PROM, Questionnaire, Pain, Function, Management

23 **Main Text**

24 **Introduction**

25 Monitoring the progression of knee and hip osteoarthritis (OA) is essential for effective
26 disease management and treatment escalation. While objective measures of joint function
27 offer practical tools for assessing disease severity, they often correlate poorly with patients'
28 subjective experiences, which can be captured through patient-reported outcome measures
29 (PROMs). PROMs are standardised tools for measuring patient-reported outcomes (PROs)
30 [1], which The Food and Drug Administration defines as “any report of the status of a
31 patient’s health condition that comes directly from the patient without interpretation of the
32 patient’s response by a clinician or anyone else” [2]. In practice, PROMs typically manifest
33 as standardised questionnaires completed by patients to capture their subjective health
34 experience, often used to track change over time.

35 Numerous studies have shown weak or no correlation between various objective measures,
36 such as the timed-up-and-go, and commonly used PROMs for knee and hip OA, including the
37 Activities of Daily Living (ADL) and Pain subscales of the Knee injury and Osteoarthritis
38 Outcome Score (KOOS) and Hip Disability and Osteoarthritis Outcome Score (HOOS) [3]
39 [4]. Similarly, the Western Ontario and McMaster Universities Osteoarthritis Index
40 (WOMAC) and Knee Society Score questionnaire has shown poor correlation with various
41 objective measures [5]. Consequently, PROMs are regarded as important clinical tools
42 amongst knee-specialist orthopaedic surgeons, with the majority of surgeons from the
43 Australian Knee Society (AKS) explicitly agreeing that PROMs improve communication and
44 improve the shared understanding of a patient’s condition. However, despite these beliefs,
45 actual clinical usage remains low. Only 48% of AKS members reported using PROMs at all
46 for clinical purposes. This proportion fell to 10% amongst surveyed general practitioners

47 (GPs) and orthopaedic surgeons from author ML's practice, where 77% list knee or hip as a
48 specialty area [6].

49 This clinical underuse is widely echoed in the orthopaedic literature. Alshehri et al. found that
50 only 5% of studied orthopaedic surgeons used PROMs regularly for clinical work [7], whilst
51 Choo et al. found that only 41% of studied hand surgeons collect PROMs at all, most
52 commonly for research purposes rather than clinical [8].

53 Several papers have also investigated barriers to general use in orthopaedics, with commonly
54 identified barriers including (1) uncertainty regarding PROM use or interpretation (2) time
55 constrains and (3) logistic or administrative concerns, such as poor accessibility to PROMs in
56 the electronic medical record and poor PROM display [8][9][10][11]. Subsequent to this,
57 common recommendations to improve orthopaedic PROM usage have included (1) improved
58 education surrounding PROMs utility through seminars, email communications, or
59 continuing education incentives such as professional development points, and (2) upgrading
60 electronic systems for easier PROM access and display [9][10][11].

61 Whilst these strategies would certainly be beneficial, we propose an alternative approach that
62 aims to "swim with the current" rather than resisting current practices. Instead of
63 implementing changes to increase use of existing PROMs, we advocate for the development
64 of new PROMs which eliminate identified barriers. This correspondence therefore seeks to
65 expand on reasons for clinical non-use of PROMs, with a particular focus on modifiable
66 factors that can guide development of future clinically practical PROMs. We conclude by
67 proposing an example of a new PROM for knee and hip osteoarthritis which is informed by
68 these insights.

69

70 **Barriers to Use and Future Development Considerations**

71 Through anonymous surveys distributed to orthopaedic surgeons and general practitioners,
 72 we have identified various barriers to clinical usage (see Table 1), many of which align with
 73 findings in the literature.

Table 1. Reasons for Lack of PROM Usage Clinically amongst Orthopaedic Surgeons and General Practitioners

Reasons for Lack of Clinical PROM Usage	Selection Rate (%)
Surgical Respondents	
Administration/implementation issues or incompatible practice setup	39
Believe PROMs will confuse an already happy doctor-patient relationship	39
Not enough consulting time	33
Too many questions	28
Too complex	28
Patients don't understand PROMs	28
Scores are for research purposes only	22
PROMs do not help to illustrate symptoms or treatment outcomes	17
Too inefficient	11
General Practitioner Respondents	
Not enough consulting time	53
Lacking ability to administer PROMs	29
Happy with current doctor-patient relationship	22

74

75 Important considerations for future PROM development were also surveyed amongst
 76 orthopaedic surgeons, GPs and members of the general public who have experienced joint or
 77 back pain.

Table 2. Important Considerations for New PROM Development amongst Orthopaedic Surgeons, General Practitioners and the General Public.

Important Considerations for Future PROM Development	Selection Rate (%)
Surgical Respondents	
Ease of patient use	90
Time efficiency	86
Easily understandable and reliable scores	76
Easy to administer	73
Easily assess outcomes following treatment choices	67
Utility as a tool to counsel patients about their current symptoms, treatment options and possible outcomes	43
Effectively and efficiently help assess patient current symptoms	40
Efficiently help improve effective treatment choices	29
Ability to enhance doctor-patient relationships	27
Improve making all appropriate treatment choices prior to specialist referral	20
Enhance the decision to prioritise a referral to a specialist if required	20
Other	14
General Practitioner Respondents	
Time efficiency	100
Ease of patient use	84
Ease of administration	75
Easily understandable	75
Reliable Scores	75
General Public	
Ability to grade symptoms into mild, moderate and severe categories	82
Ability to suggest when a medical review would be beneficial	82
Ability to suggest when a surgical review would be beneficial	73

78

79 Notably, 91% of GPs expressed desire or potential desire for a new a simple PROM.

80 In light of these results and existing literature, we have identified three actionable strategies

81 to guide future PROM development:

82 1. Reduce Length - Time constraints are one of the most commonly cited barriers to
83 PROM use, both in our survey and the literature. It was the third most significant
84 reason among surveyed surgeons and the most significant among GPs. Several other
85 barriers, such as “too many questions,” “too complex,” “too inefficient,” or
86 “administration/implementation issues”, can be seen as downstream effects of
87 excessive length and complexity. A shorter, simpler PROM would reduce these burdens
88 and make clinical implementation more feasible in the current time-constrained
89 healthcare landscape.

90 Ease of administration and patient use were also prioritised by the vast majority of
91 surveyed clinicians, both of which may improve with reduced length. Importantly,
92 although most existing PROMs (e.g. KOOS – 42 questions [12], HOOS – 40 questions
93 [13], WOMAC – 24 questions [14]) involve multiple-question subscales to assess
94 individual PROs, research has demonstrated favourable psychometric properties for
95 single-item measures of pain and joint function in knee and hip OA specifically.

96 For instance, an 11-point Numerical Rating Scale (NRS) assessing joint function
97 showed strong correlation with the WOMAC-Function subscale and demonstrated
98 moderate-to-large responsiveness to NSAID treatment [15]. Similarly, a Visual
99 Analogue Scale (VAS) for pain showed modest correlation with the WOMAC Pain
100 subscale [16]. Shortened versions of existing PROMs, such as the 12 question HOOS
101 and short-form WOMAC, have also shown satisfactory validity, responsiveness and
102 reliability [17][18].

103 Short PROMs could be administered on paper and manually entered into the electronic
104 medical record allowing for ease of access to PROMs and ease of recall, which was
105 considered an important consideration by 67% of surgical respondents. This

106 circumvents the unideal existing electronic PROM systems which was a commonly
107 identified barrier in the literature.

108

109 2. Incorporate Disease Severity Stratification – Stratifying PROM scores into clinically
110 meaningful categories, such as mild, moderate, and severe, can enhance patient
111 understanding and emphasise clinical relevance. Whitebird et al. found that many
112 surgeons report patients struggle to interpret their scores. One surgeon noted, “patients
113 have no idea what to compare their numbers to”, and others expressed the importance
114 of “patient-facing” PROMs that support communication and engagement [11]. This is
115 echoed in our surveys, with “ease of patient use” and “easily understandable” being
116 prominent important considerations for future development. Translating abstract
117 numerical scores into familiar, digestible terms may help to achieve these goals.
118 Furthermore, 82% of respondents from the general public wanted PROMs to clearly
119 grade symptoms into mild, moderate, and severe categories. Incorporating this feature
120 directly addresses both patient and clinician needs for more intuitive scores.

121

122 3. Inbuilt Treatment Recommendations – Embedding treatment and referral guidance
123 within each symptom severity category would address the major barrier identified in
124 the literature of clinician uncertainty around PROM score interpretation. This strategy
125 also opposes the perception that PROMs are “for research purposes only” or that they
126 “do not help to illustrate symptoms or treatment outcomes”, held by 22% and 17% of
127 surveyed surgeons, respectively.

128 Clear treatment suggestions and referral advice could enhance the clinical utility of
129 PROMs as decision-support tools. In our survey, 43% of surgeons identified patient

130 counselling on symptoms, treatment and outcomes as an important consideration, 29%
131 highlighted treatment decision-making support, and 20% for referral guidance. Among
132 members of the general public, 73% and 82% expressed desire for PROMs that can
133 appropriately recommend surgical and medical review, respectively. Embedding such
134 guidance could accelerate referrals for patients likely to benefit from surgery, while also
135 reducing unnecessary referrals.

136 Analysis of predicted disease progression and treatment recommendations for each
137 zone should be incorporated into early psychometric evaluation of new PROMs.

138 Perhaps even further predictive factors, such as the rate of change of PROM score from
139 presentation, could inform recommended treatment. Regardless, incorporation of
140 treatment recommendations into the PROM itself, rather than relying on subsequent
141 interpretation or unaffiliated research, may significantly boost clinical uptake.

142

143 **Exemplar PROM**


144 With these strategies in mind, we put forward an example PROM (see Appendix B), the Basic
145 Orthopaedic Rapid Indicator Score (BORIS), which uses two single-scale measures to assess
146 the PROs of joint pain and function. These individual scores are combined, placing the
147 patient into one of three zones: mild, moderate or severe. Suggested treatment strategies for
148 each zone are presented.

149 Question 1 asks: “Rate the pain you have experienced during your daily activities over the
150 last 7 days due to the joint pain for which you are seeing the doctor today.” This is scored
151 using a 10 centimetre VAS, from 0 (no pain) to 10 (extreme pain). A ruler can be utilised to
152 measure the exact score.

153 Question 2 asks: “What degree of difficulty have you experienced during your daily activities
 154 over the last 48 hours due to the joint pain for which you are seeing the doctor today?”. This
 155 is scored on an 11-point NRS from 0 (not affected) to 10 (highly affected). Question 1 is
 156 worded similarly to the 11-point NRS found to correlate strongly with the WOMAC-Function
 157 subscale [15].

158 For both questions, a score of 5 (the midpoint) translates to zero points, with scores to the
 159 right translating to negative points and scores to the left translating to positive points (see
 160 Figure 1). For example, a score of 7 would yield -2 points, while a score of 2 would yield 3
 161 points (see Figure 1). The points are then added, and the cumulative score places the patient
 162 into one of three zones. Converting the raw scores, which are always greater than 0, to total
 163 points, between -10 and +10, allows for movement from negative to positive total points with
 164 treatment, providing positive psychological feedback and further increasing intuitive
 165 interpretation. A negative score may also affirm patients’ experiences.

166



168 *Figure 1*

169 Zone 1 (total points > 2) indicates mild symptoms. Conservative management is the most
 170 suitable approach at this stage, which includes lifestyle modifications, low-impact exercise,
 171 over-the-counter analgesics like paracetamol or NSAIDs, and involvement from allied health
 172 professionals such as physiotherapists and exercise physiologists. Zone 2 (total points
 173 between -2 and 2) signifies moderate symptoms. Within this zone a GP consultation is

174 suggested, with an emphasis on advancing non-surgical management. Recommendations
175 might include stronger analgesics, such as opioids. If management fails despite maximising
176 non-operative strategies, a surgical referral is advised. Zone 3 (total points < -2) denotes
177 severe symptoms. GP consultation and surgical referral are both advisable. While non-
178 operative management may lead to some improvement in symptoms, surgical intervention
179 may likely be required.

180 Despite its simplicity, BORIS remains a standardised patient-completed questionnaire
181 designed to assess the PROs of pain and joint function. As such, it meets the essential
182 definition of a PROM. BORIS is a PROM that may be used by general practitioners and
183 orthopaedic surgeons, or other clinicians, to track symptom progression over time, as well as
184 inform treatment and referral options.

185 BORIS and other PROMs which may be developed using these strategies are not intended to
186 replace more multidimensional PROMs used in research and outcomes registries. Instead,
187 they are developed in response to clinician and patient feedback, to enable faster,
188 interpretable, and actionable PROM use in routine care. By aligning with workflow realities
189 and embedding care direction into the scoring, BORIS represents a new class of PROMs
190 designed for implementation-first use in musculoskeletal care.

191 Psychometric evaluation for BORIS or any other tool developed using these strategies is
192 required, and this will be the focus of future research.

193

194 **Conclusion**

195 Despite widespread acknowledgment of their clinical value, PROMs remain significantly
196 underutilized in routine care for knee and hip osteoarthritis. Our findings, in conjunction with
197 existing literature, have revealed 3 actionable strategies for future PROM development with

198 the goal of increased clinical uptake. These strategies include reduced questionnaire length,
199 incorporating symptom severity stratification and embedding treatment guidance. BORIS
200 provides an exemplar of how these strategies may be implemented. By prioritizing
201 implementation-first design, PROMs developed using these strategies have the potential to
202 bridge the gap between perceived value and real-world clinical use. Future research should
203 now focus on further developing and psychometrically evaluating such tools.

204

205 **List of Abbreviations**

206 ADL – Activities of Daily Living

207 AKS – Australian Knee Society

208 GP – General Practitioner

209 HOOS – Hip Disability and Osteoarthritis Outcome Score

210 KOOS – Knee injury and Osteoarthritis Outcome Score

211 NRS – Numerical Rating Scale

212 OA – Osteoarthritis

213 PRO – Patient Reported Outcome

214 PROM – Patient Reported Outcome Measure

215 VAS – Visual Analogue Scale

216 WOMAC – Western Ontario and McMaster Universities Osteoarthritis Index

217

218 **Declarations**

219 **Ethics Approval and Consent to Participate**

220 The surveys analysed in this manuscript were originally conducted as market research.

221 **Consent for publication**

222 Not Applicable

223 **Availability of data and materials**

224 All data analysed during this study are included in this published article and appendix.

225 **Competing interests**

226 AS – None

227 ML – Founder of MAXM, a company producing post-knee arthroplasty rehabilitation

228 devices. ML is an orthopaedic surgeon and member of Orthopaedics SA and the Australian

229 Knee Society.

230 **Funding**

231 Self-funded by authors

232 **Authors' contributions**

233 AS – Data interpretation, writing, review and editing

234 ML – Conceptualisation, data curation, supervision, review and editing

235 **Acknowledgements**

236 Alicia Mitchell: Writing advise.

237 **References**

- 238 1. Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome
239 Measures (PROMs). *Health Serv Insights*. 2013;6:61-8.
- 240 2. Food and Drug Administration. Guidance for industry: Patient-reported outcome
241 measures: Use in medical product development to support labeling claims. Rockville, MD:
242 US Department of Health and Human Services, 2009.
- 243 3. Selzer F, Zarra MB, MacFarlane LA, Song S, McHugh CG, Bronsther C, Huizinga J,
244 Losina E, Katz JN. Objective performance tests evaluate functional aspects overlooked by
245 self-reported assessments in knee osteoarthritis. *Osteoarthr Cartil Open*. 2022;4(4):100311.
- 246 4. Dayton MR, Judd DL, Hogan CA, Stevens-Lapsley JE. Performance-Based Versus Self-
247 Reported Outcomes Using the Hip Disability and Osteoarthritis Outcome Score Following
248 Total Hip Arthroplasty. *Aust J Phys Med Rehabil*. 2016;95(2):132-8.
- 249 5. Bolink SA, Grimm B, Heyligers IC. Patient-reported outcome measures compared to
250 inertial performance-based outcome measures: A prospective study of patients undergoing
251 primary total knee arthroplasty. *Knee*. 2015;22(6):618-23.
- 252 6. Orthopaedics SA. Our Doctors [Internet]. Adelaide, SA: Orthopaedics SA, 2025. Available
253 from: <https://www.orthosa.com.au/doctors/>.
- 254 7. Alshehri F, Alarabi A, Alharthi M, Alanazi T, Alohal A, Alsaleem M. Use of patient-
255 reported outcome measures (PROMs) by orthopedic surgeons in Saudi Arabia. *Journal of*
256 *Orthopaedic Surgery and Research*. 2020;15(1):598.
- 257 8. Choo S, Parola R, Kirby B, London DA. The Use of Patient-Reported Outcomes in
258 Clinical Practice: A National Survey of Hand Surgeons. *Journal of Hand Surgery Global*
259 *Online*. 2025;7(1):41-7.

- 260 9. Heath EL, Harris IA, Berkovic D, Ackerman IN. How Can the Use of Patient-Reported
261 Outcomes Data by Orthopaedic Surgeons Be Improved? A National Qualitative Study.
262 *Clinical Orthopaedics and Related Research*®. 9900:10.1097/CORR.0000000000003503.
- 263 10. Heath EL, Harris IA, Romero L, Ackerman IN. A systematic review of qualitative studies
264 examining barriers and facilitators to orthopaedic surgeon engagement with patient-reported
265 outcome measures data. *Journal of Patient-Reported Outcomes*. 2024;8(1):144.
- 266 11. Whitebird RR, Solberg LI, Ziegenfuss JY, Norton CK, Chrenka EA, Swiontkowski M, et
267 al. What Do Orthopaedists Believe is Needed for Incorporating Patient-reported Outcome
268 Measures into Clinical Care? A Qualitative Study. *Clin Orthop Relat Res*. 2022;480(4):680-7.
- 269 12. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and
270 Osteoarthritis Outcome Score (KOOS)—Development of a Self-Administered Outcome
271 Measure. *Journal of Orthopaedic & Sports Physical Therapy*. 1998;28(2):88-96.
- 272 13. Nilsson AK, Lohmander LS, Klässbo M, Roos EM. Hip disability and osteoarthritis
273 outcome score (HOOS) – validity and responsiveness in total hip replacement. *BMC*
274 *Musculoskeletal Disorders*. 2003;4(1):10.
- 275 14. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of
276 WOMAC: a health status instrument for measuring clinically important patient relevant
277 outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J*
278 *Rheumatol*. 1988;15(12):1833-40.
- 279 15. Ornetti P, Dougados M, Paternotte S, Logeart I, Gossec L. Validation of a numerical
280 rating scale to assess functional impairment in hip and knee osteoarthritis: comparison with
281 the WOMAC function scale. *Ann Rheum Dis*. 2011;70(5):740-6.

- 282 16. Bjerre-Bastos JJ, Li Y, Andersen JR, Christiansen C, Karsdal MA, Bihlet AR. The
283 association between a single-question VAS pain rating and the weight-bearing and non-
284 weight-bearing domains of WOMAC pain: a post-hoc analysis based on data from two phase
285 3 clinical trials. *Osteoarthritis and Cartilage*. 2021;29:S241-S2.
- 286 17. Gandek B, Roos EM, Franklin PD, Ware JE. A 12-item short form of the Hip disability
287 and Osteoarthritis Outcome Score (HOOS-12): tests of reliability, validity and
288 responsiveness. *Osteoarthritis and Cartilage*. 2019;27(5):754-61.
- 289 18. Yang KG, Raijmakers NJ, Verbout AJ, Dhert WJ, Saris DB. Validation of the short-form
290 WOMAC function scale for the evaluation of osteoarthritis of the knee. *J Bone Joint Surg Br*.
291 2007;89(1):50-6.